IPN, Delhi, India. Open 10-6pm

+91 9891296838 / 9811747774

Fruquintinib Capsules, for oral use Initial U.S. Approval: 2023

Fruquintinib Capsules, for oral use Initial U.S. Approval: 2023

Fruquintinib is used to treat colorectal cancer (cancer of the colon or rectum) that has spread throughout the body in patients who have received other cancer treatments (eg, fluoropyrimidine, oxaliplatin, and irinotecan) that did not work well.

Approval Date: 2023
Proprietary Name: FRUZAQLA
Active Ingredient(s): fruquintinib
FDA-approved use: To treat patients with Colorectal cancer
Dosage Form: Capsules
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import “Fruquintinib Capsules” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

Contact Info

CORPORATE OFFICE:
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.

MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398

EMAIL ID:
info@indianpharmanetwork.co.in

FAX NUMBER:
+91-11-26532129

Query For Fruquintinib Capsules, for oral use Initial U.S. Approval: 2023

Approved accessible "Fruquintinib Capsules"

Fruquintinib is approved to treat:

  • Colorectal cancer that has spread to other parts of the body. It is used in adults who have received previous treatment with a fluoropyrimidine, oxaliplatin, irinotecan hydrochloride, and an anti-VEGF therapy. Patients whose cancer has the wild-type KRAS gene may also have received an anti-EGFR therapy.

Fruquintinib is also being studied in the treatment of other types of cancer.

How can 1 go about obtaining Fruquintinib Capsules?

If Fruquintinib Capsules are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).

FRUZAQLA (fruquintinib) capsules, for oral use Initial U.S. Approval: 2023

Indian Pharma Network (IPN), New Delhi. India

Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa

Indian Pharma Network
60/4 1st Floor, T&T Building, Indian Oil Complex, Yusuf Sarai, New Delhi, Delhi 110016

Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398